Regarding HoR-positive disease, an ongoing clinical trial is still assessing the CDK4/6i potential benefit: the eMonarcHER trial (NCT04752332) is evaluating abemaciclib plus ET in patients with triple-positive BC who had completed adjuvant HER2-targeted therapy. This evidence concerns the gene CDK4 and breast cancer.